Singapore | May 4, 2026
Specialised Therapeutics has announced that NIKTIMVO® (axatilimab) has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia, marking a significant milestone in the treatment of chronic graft-versus-host disease (cGVHD). This approval positions Australia as the first country globally to grant marketing authorization for NIKTIMVO following its earlier U.S. FDA approval, reinforcing the growing global momentum for this first-in-class CSF-1R blocking antibody therapy.
Regulatory Approval Expands Treatment Options for cGVHD
The TGA approval under the Priority Review pathway enables the use of NIKTIMVO for adult and pediatric patients aged 6 years and older who have failed at least two prior lines of systemic therapy. Chronic GVHD remains a serious and potentially life-threatening condition that occurs following allogeneic stem cell transplantation, affecting approximately 40–50% of transplant recipients and often involving multiple organs.
NIKTIMVO introduces a novel therapeutic mechanism, targeting the colony stimulating factor-1 receptor (CSF-1R), which plays a central role in inflammation and fibrosis associated with cGVHD. By selectively inhibiting this pathway, the therapy addresses key disease drivers, offering a new approach for patients with limited treatment options and high unmet medical need.
Clinical Trial Data Demonstrates Strong Efficacy and Safety
Advertisement
The approval is supported by results from the global Phase 2 AGAVE-201 clinical trial, which evaluated the efficacy and safety of axatilimab in 241 patients with refractory cGVHD across 16 countries. The study demonstrated a high overall response rate (ORR) of 74%, with 60% of patients maintaining their response at 12 months, indicating durable clinical benefit.
Importantly, NIKTIMVO was found to have a manageable safety profile, with the most common adverse events including fatigue, elevated liver enzymes, and infusion-related reactions. No fatal or serious adverse events were reported in the clinical study, supporting its potential as a well-tolerated treatment option. These findings highlight the therapy’s role in advancing GxP-compliant clinical development and regulatory approval pathways.
Scientific Innovation and Global Impact
The development of NIKTIMVO is rooted in pioneering Australian research, which identified the cellular mechanisms driving cGVHD and enabled the discovery of a targeted antibody therapy to block disease progression. This innovation underscores the importance of translational research in advancing novel biologic therapies for complex immune-mediated diseases.
The approval also reflects ongoing efforts to expand access to advanced therapies across global markets. Specialised Therapeutics is currently exploring reimbursement pathways through Australia’s Pharmaceutical Benefits Scheme (PBS) to ensure equitable patient access. Additionally, ongoing clinical studies are evaluating NIKTIMVO in combination therapies and new indications, further expanding its therapeutic potential.
The approval of NIKTIMVO in Australia represents a major advancement in the treatment of chronic GVHD, offering a first-in-class biologic therapy with strong clinical efficacy and a novel mechanism of action. This milestone highlights the importance of innovation in Bio-Pharma and GxP-regulated clinical development, providing new hope for patients with limited treatment options and reinforcing the role of targeted therapies in improving patient outcomes.
Source: Specialised Therapeutics press release
